Advertised as the first Alzheimer's drug capable to treat the cognitive decline coming with this infamous disease, Biogen's Aduhelm has just been withdrawn from the market. The only treatment for this brain disorder approved in the US remains Leqembi, co-manufactured by Biogen and Japanese company Eisai.